Carnegie acted as sole book-runner in the directed new share issue of 9.5 million new shares at a price of NOK 4.25 per share. Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes.January 2013.
Healthcare
Directed new share issue in Biotec Pharmacon (NO) — NOK 40 million
January 2013